Coverage
-
May 22, 2014
Two qui tam plaintiffs on Thursday freed four medical companies from a suit claiming they were involved in a kickback scheme with Amgen Inc. to market its anemia drug off-label, ending a decadelong False Claims Act dispute over the drugmaker's admitted misbranding of its Aranesp anemia drug.
1 other articles on this case.
View all »